The Organ Protection of Astragalus in Subjects With Metabolic Syndrome

Lanzhou University

Status and phase: Completed; Phase 3

Conditions: Metabolic Syndrome

Treatments: Drug: high dose astagalus; Drug: low dose Astragalus

Study type: Interventional

Funder types: Other

Identifiers

NCT01847807

MS2304

Details and patient eligibility

About

Metabolic syndrome have the damages on tissues and organs in heart、kindey and vessels. In this study, prospective randomized, controlled, parallel designed ,different doses of Astragalus Mongolia, Gansu Longxi produce treat on the MS patients, and then use real-time quantitative PCR and Western Blotting to detect the index of oxidative stress 、angiotensin-converting enzyme 2 mRNA expression and proteins.

Enrollment: 210 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. age 18 years or older, meet the diagnostic criteria of MS
2. non-allergic with the astragalus
3. agree to conduct clinical trials and those who signed the informed consent

Exclusion criteria

1. patients with resistant hypertension
2. renal disease requiring dialysis
3. heart failure NYHA ⅢorⅣ;
4. complications of diabetes
5. arteritis
6. cancer
7. thyroid disease
8. unstable coronary heart disease
9. peripheral vascular disease
10. acute cerebral vascular disease11.pregnancy、 planned pregnancy
11. patients with anti-oxidants
12. acute infection
13. other organic dysfunction, such as the liver, respiratory system, blood system, and other rheumatic diseases.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

210 participants in 3 patient groups

High-dose Astragalus group

Active Comparator group

Description:

treatment with 10 gram astragalus

Treatment:

Drug: high dose astagalus

Low-dose Astragalus group

Active Comparator group

Description:

treatment with 5 gram astragalus

Treatment:

Drug: low dose Astragalus

MS control

No Intervention group